Anlotinib + Benmelstobart + HAIC in Unresectable HCC: A Phase II Study
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
To evaluate the efficacy and safety of anlotinib combined with benmelstobart and HAIC as first-line treatment for unresectable hepatocellular carcinoma.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18-75 lat, dowolna płeć
- •Potwierdzona diagnoza nieoperacyjnego raka wątroby
- •Co najmniej jeden widoczny guz o rozmiarze co najmniej 10 mm
- •Nigdy wcześniej nie leczone przeciwnowotworowo (lub wznowa po poprzedniej operacji)
- •Prognoza przeżycia co najmniej 12 tygodni
- •Dobra ogólna kondycja zdrowotna (ECOG 0-1)
- •Prawidłowe wartości krwi (hemoglobina, płytki krwi, granulocyty)
- •Prawidłowe funkcje wątroby i nerek
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- September 8, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Guangzhou, China
Trial contact
Changzhen Shang, M.D, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/9/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.